SBIR Phase I: Engineering Platform for the Nanoformulations of Water Insoluble Drugs Using Supercritical Antisolvent Process with Enhanced Mass Transfer

Information

  • NSF Award
  • 0215181
Owner
  • Award Id
    0215181
  • Award Effective Date
    7/1/2002 - 22 years ago
  • Award Expiration Date
    12/31/2002 - 21 years ago
  • Award Amount
    $ 99,901.00
  • Award Instrument
    Standard Grant

SBIR Phase I: Engineering Platform for the Nanoformulations of Water Insoluble Drugs Using Supercritical Antisolvent Process with Enhanced Mass Transfer

This Small Business Innovation Research (SBIR) Phase I project proposes to develop a flexible platform for nano-formulations of water insoluble drugs. As the practice of medicine progresses towards "complete cure for diseases", delivering new drugs to specific areas to target specific tissues becomes an important objective of overall pharmaceutical research. Unfortunately many new drugs have poor water solubility that reduces their bioavailability. Carefully formulated nanoparticles and nanospheres are reported to have therapeutic advantages such as bioavailability, ability to avoid reticuloendothelial system (RES) removal, and direct tumor targeting. This project will develop the Supercritical Anti-Solvent with Enhanced Mass Transfer (SAS-EM) Process for producing nanoparticles of water insoluble drugs and encapsulating<br/>them in biodegradable polymers as nanospheres. The three key steps in the Phase I study include : (1) Phase behavior studies to identify the suitable solvent and experimental conditions, (2) Particle formation studies where nanoparticles of said drugs are produced using supercritical antisolvent process with enhanced mass transfer, and (3) Characterization of the nanoparticles/nanospheres for particle size, size distribution, and crystallinity. Light scattering techniques will be used to measure the size distribution complemented with Scanning electron microscopic visualization. X-ray diffraction measurements will be used to describe the crystallinity.<br/><br/>The commercial applications of this project are in the area of pharmaceutical drug delivery.

  • Program Officer
    Om P. Sahai
  • Min Amd Letter Date
    6/10/2002 - 22 years ago
  • Max Amd Letter Date
    6/10/2002 - 22 years ago
  • ARRA Amount

Institutions

  • Name
    Thar Technologies, Inc.
  • City
    Pittsburgh
  • State
    PA
  • Country
    United States
  • Address
    730 William Pitt Way
  • Postal Code
    152381333
  • Phone Number
    4128263939

Investigators

  • First Name
    Poongunran
  • Last Name
    Muthukumaran
  • Email Address
    poongs@thartech.com
  • Start Date
    6/10/2002 12:00:00 AM

FOA Information

  • Name
    Health
  • Code
    203000